

Developing an antisense oligonucleotide treatment for Spinocerebellar Ataxia Type 3 Toonen, L.J.A.

Citation

Toonen, L. J. A. (2018, May 31). *Developing an antisense oligonucleotide treatment for Spinocerebellar Ataxia Type 3*. Retrieved from https://hdl.handle.net/1887/62616

Version:	Not Applicable (or Unknown)	
License:	<u>Licence agreement concerning inclusion of doctoral thesis in the</u> <u>Institutional Repository of the University of Leiden</u>	
Downloaded from:	https://hdl.handle.net/1887/62616	

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <u>http://hdl.handle.net/1887/62616</u> holds various files of this Leiden University dissertation.

Author: Toonen, L.J.A. Title: Developing an antisense oligonucleotide treatment for Spinocerebellar Ataxia Type 3 Issue Date: 2018-05-31



Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice

Lodewijk J.A. Toonen, Frank Rigo, Haico van Attikum, Willeke M.C. van Roon-Mom (2017). Mol Ther Nucleic Acids, 8, 232-242

ABSTRACT

Spinocerebellar ataxia type 3 (SCA3) is a currently incurable neurodegenerative disorder caused by a CAG triplet expansion in exon 10 of the ATXN3 gene. The resultant expanded polyglutamine stretch in the mutant ataxin-3 protein causes a gain of toxic function, which eventually leads to neurodegeneration. One important function of ataxin-3 is its involvement in the proteasomal protein degradation pathway, and long-term downregulation of the protein may therefore not be desirable. In the current study, we made use of antisense oligonucleotides to mask predicted exonic splicing signals, resulting in exon 10 skipping from ATXN3 pre-mRNA. This led to formation of a truncated ataxin-3 protein lacking the toxic polyglutamine expansion, but retaining its ubiquitin binding and cleavage function. Repeated intracerebroventricular injections of the antisense oligonucleotides in a SCA3 mouse model led to exon skipping and formation of the modified ataxin-3 protein throughout the mouse brain. Exon skipping was long lasting, with the modified protein being detectable for at least 2.5 months after antisense oligonucleotide injection. A reduction in insoluble ataxin-3 and nuclear accumulation was observed following antisense oligonucleotide treatment, indicating a beneficial effect on pathogenicity. Together, these data suggest that exon 10 skipping is a promising therapeutic approach for SCA3.

INTRODUCTION

Spinocerebellar ataxia type 3 (SCA3) is an hereditary neurodegenerative disorder characterized by ataxia, usually presenting in the third to sixth decade of life.¹ Pathoanatomical studies of SCA3 patient brains have shown neurodegeneration in the cerebellum, thalamus, midbrain, pons, medulla and spinal cord.² SCA3 is one of 9 known polyglutamine (polyQ) disorders. The causative mutation for polyQ disorders is a CAG codon repeat expansion in the coding region of a gene, which upon translation leads to an expanded glutamine amino acid stretch in the causative protein. It is thought that the polyQ expansion leads to a gain of toxic protein function.³ In the case of SCA3, the CAG repeat expansion is located in exon 10 of the *ATXN3* gene, encoding the ataxin-3 protein.⁴ In the normal population, an *ATXN3* CAG repeat length of 10 to 51 repeats is observed, whilst SCA3 patients have repeat lengths of 55 or longer.⁵

Ataxin-3 is a ubiquitously expressed deubiquitinating enzyme of around 42 kDa with its main function in the proteasomal protein degradation pathway.⁶ Several ataxin-3 isoforms have been described⁷ with the predominant ataxin-3 isoform (NM_004993) in human and mouse brain containing 3 ubiquitin interaction motifs (UIMs).^{8,9} It has been shown that the interaction between ataxin-3 and K48-linked poly-ubiquitin chains is dependent on the first two UIMs, whilst the third UIM located C-terminally of the polyQ stretch appears dispensable for this process.^{10, 11} Upon binding of poly-ubiquitin chains by the UIMs, the N-terminal catalytic Josephin domain of ataxin-3 can cleave these chains. Through this process, ataxin-3 can facilitate substrate entry into the proteasome, as well as mediate other ubiquitin-dependent pathways.^{11,12}

Given the monogenetic nature, SCA3 is an ideal candidate for therapies that specifically target the *ATXN3* gene product. Indeed, several RNA interference (RNAi) strategies that downregulate ataxin-3 protein expression have been investigated over the last decade. Non-allele specific silencing of ataxin-3 was found to reduce neuropathology in a SCA3 rat model.¹³ Additionally, by making use of a SNP associated with the mutant *ATXN3* allele (rs12895357), an allele specific RNAi-mediated reduction of mutant ataxin-3 decreased neuropathological abnormalities and/or motor deficits in both SCA3 rats and mice.¹⁴⁻¹⁶ Antisense oligonucleotides (AONs) are another tool under investigation for therapeutic intervention in SCA3. Particularly for use in brain, AONs offer several favorable properties, including good distribution throughout the brain after infusion in the cerebrospinal fluid, excellent uptake by neurons and other brain cells, high stability with a half-life of several months, and a promising tolerability in clinical trials thus far.¹⁷ Another advantage of using AONs is that they can also be used to redirect splicing by including or excluding specific exons.

Here we describe an AON based strategy to redirect splicing of the ataxin-3 pre-mRNA. The aim of this approach is to remove the toxic polyQ repeat from the mutant ataxin-3 protein thereby removing the cause of SCA3. Using an AON targeting exon 10 of *ATXN3* this exon is removed from the pre-mRNA, resulting in a truncated ataxin-3 protein consisting of 291 amino acids with a predicted mass of 34 kDa. Functional testing of the truncated protein lacking the polyQ domain and the third UIM showed that this modified ataxin-3 can still bind ubiquitin chains similar to wildtype ataxin-3. Finally, the AON was tested in the MJD84.2 SCA3 mouse

model using repeated bolus injection in the lateral ventricle of the brain. Remarkably, this lead to widespread distribution of the AON with ataxin-3 protein modification observed throughout the brain.

MATERIALS AND METHODS

Antisense oligonucleotides design and synthesis

Oligonucleotides targeting exon 10 (Table 1) of the human *ATXN3* transcript NM_004993 were designed according to previously described guidelines.^{18, 19} AONs targeted predicted exonic splicing enhancer sites according to the Human Splicing Finder.²⁰ Specificity of the AONs was checked using BLAST analysis. The synthesis and purification of the oligonucleotides was performed as described previously.²¹ AONs were fully modified with 2'-O-methoxyethylribose nucleotides and a phosphorothioate backbone. Cytosine residues were methylated to reduce immunostimulatory effects of the oligonucleotides *in vivo*.²²

Cell culture

SCA3 fibroblast (GM06153) cell lines were obtained from Coriell Cell Repositories (Camden, USA) and maintained in Minimal Essential Medium (MEM) (Gibco, Invitrogen, Carlsbad, USA), containing 15% fetal bovine serum (FBS) (Clontech, Palo Alto, USA), 1% Glutamax (Gibco), and 100 U/ml penicillin/streptomycin (Gibco).

Human U2OS 2-6-3 cells containing 200 copies of a LacO (256 ×)/TetO (96 ×)-containing cassette of ~4Mbp,²³ were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco), supplemented with 10% FBS, 1% glutamax, and 100 U/ml penicillin/streptomycin. All cells were grown at 37°C and 5% CO₂.

Transfections

Transfections of AONs was performed as described previously.²⁴ Briefly, fibroblasts were re-plated the day before transfection. AONs were diluted to 200nM in MEM medium without supplements containing 0.3% lipofectamine (Life Technologies, Paisley, UK). The cells were incubated with the transfection mixture for 4 hours, after which a three times volume of normal

AON name	Sequence (5' to 3')
10.1	GCTGTTGCTGCTTTTGCTGCTG
10.1-2	CTGTTGCTGCTTTTGCTGCT
10.2	GAACTCTGTCCTGATAGGTC
10.3	CTAGATCACTCCCAAGTGCT
10.4	ATAGGTCCCGCTGCTGCT

Table 1. ATXN3 exon 10 antisense oligonucleotides

growth medium was added. Cells were harvested one day after transfection for RNA analysis, or 2 days after transfection for protein analysis.

Plasmid transfections were performed similar to AON transfections using 1 to 1.5 μ g of plasmid DNA (per 9.6 cm² well) in 0.6 ml MEM with 0.6% lipofectamine. Cells were imaged for GFP or mCherry protein expression the next day using a Leica DM-5500B fluorescent microscope (Leica Microsystems, Buffalo Grove, USA) at 63x magnification as previously described.²⁵

Mice and oligonucleotide injections

MJD84.2 SCA3 mice²⁶ were obtained from Jackson laboratories (Bar Harbor, Maine, USA), stock number 012705. All animal experiments were carried out in accordance with European Communities Council Directive 2010/63/EU and were approved by the Leiden University animal ethical committee. Animals were housed singly after surgery in individually ventilated cages with a 12 hour light/dark cycle. Food and water were available *ad libitum*. Mice were bred with wildtype C57/BL6 mice (Charles River, Saint-Germain-Nuelles, France) to obtain wildtype or hemizygous SCA3 animals. Mice were genotyped using ear clip tissue material and a Phire animal tissue direct PCR kit (ThermoFisher scientific, Waltham, MA, USA), using forward primer hAtxn3int10fw1 and reverse primer hAtxn3int10rev1 (see Table 2) targeting the human *ATXN3* transcript, and mAtxn3int10fw1 and mAtxn3int10rev1 primers targeting mouse ataxin-3 as positive control for DNA isolation. Multiplex PCR was performed following manufacturer's instructions with an annealing temperature step of 61.5°C, 20 sec of extension at 72°C and a total of 35 PCR cycles.

For AON injections, a total of 34 male mice aged 2 to 2.5 months and weighing approximately 25 grams were anesthetized using 1.5% isoflurane gas anaesthesia and mounted on a Kopf

Target gene	Primer name	Application	Sequence (5' to 3')
ATXN3	hATXN3_FL_rev2	cDNA synthesis	TCCTACAACCGACGCATTGT
ATXN3	hATXN3_FL_Fw1	cloning	ATGGAGTCCATCTTCCACGA
ATXN3	hATXN3_FL_Rev	cloning	CGCATTGTTCCACTTTCCCA
ATXN3	hATXN3ex4Fw1	RT-PCR	GCCTTGAAAGTTTGGGGGTTT
ATXN3	hATXN3ex11Rev1	RT-PCR	ACAGCTGCCTGAAGCATGTC
ATXN3	MJD_gen_fw1	genotyping PCR	ATACTTCACTTTTGAATGTTTCAGAC
ATXN3	MJD_gen_rev1	genotyping PCR	GAATGGTGAGCAGGCCTTAC
mATXN3	mAtxn3int10fw1	genotyping PCR	GCGTTGTTTTAACAGATATTCACG
mATXN3	mAtxn3int10rev1	genotyping PCR	TGTGAATGGACAGAAAGCAAA
ATNX3	hATXN3_∆C14_fw	mutagenesis	GAAACAAGAAGGCTCACTTGCTCAACATT
			GCCTGAA
ATXN3	hATXN3_ Δ C14_rev	mutagenesis	TTCAGGCAATGTTGAGCAAGTGAGCCTTC
			TTGTTTC

Table 2. Primer sequences

stereotactic device (David Kopf instruments, Tujunga, USA). Cannulas of 26 gauge and 3mm in length (Plastics1, Anaheim, CA, USA) were implanted in the right lateral ventricle, according to the following coordinates: 0.2 mm posterior and 1.0 mm lateral to bregma, and was lowered to a depth of 2.2 mm from the skull surface. The cannulas were subsequently fixed to the skull surface using dental cement, and closed with a screw-on internal dummy cannula. AONs for in vivo injections were dissolved in sterile PBS without calcium or magnesium to a concentration of 50 μ g/ μ l as determined by UV spectrometry, and filtered using a 0.22 μ m spin column filter. AONs or PBS were injected intracerebroventricular (ICV) through a 28 gauge needle placed in the guide cannula at a rate of 1 μ /min using a Hamilton syringe mounted in a syringe infusion pump (Stoelting, Wood Dale, IL, USA). The first AON injection consisting of 500 µg in 10 µl was performed under anaesthesia. Two additional ICV AON injections of 250 μ g in 5 μ l each were performed 2 and 3 weeks after surgery in freely moving mice, resulting in a total dose of 1 mg AON per mouse. Bodyweight was recorded every week post-surgery. Mice were sacrificed 3.5 months after surgery. The left hemisphere was dissected and snap frozen in liquid nitrogen, the right hemisphere was placed in 4% paraformaldehyde and fixed overnight at 4 °C. The fixed tissue was placed in 30% sucrose the next day and snap frozen in isopentane on dry ice.

RNA isolation and RT-PCR

Cells were detached by trypsinization (Life Technologies) and subsequently spun down. RNA was collected from the cell pellets using the Reliaprep RNA Cell Miniprep kit (Promega, Madison, USA) according to manufacturer's instructions. RNA from mouse brain tissue was obtained from fresh frozen material by homogenisation with a bullet blender BBX24 (Next Advance, Averill Park, US) for 3 minutes on setting 8, using pink beads (Next Advance), 500 μ l Trizol (Ambion, Thermo Fisher scientific), and approximately 30 mg of tissue. After 5 minutes of incubation, 100 μ l of chloroform was added and samples were spun down at 10.000g for 15 min. The aqueous phase was removed and added to an equal volume of 70% ethanol. Further RNA purification was performed using the PureLink RNA mini kit (Thermo Fisher scientific) in accordance with the manufacturer's protocol and using a 15 min DNase step. RNA was eluted in 80 μ l nuclease free water.

For cDNA synthesis, 500 ng of RNA was used as input for the Transcriptor First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany). The cDNA synthesis reaction was performed using oligoDT primers, or a gene-specific primer in the 3' UTR region of human *ATXN3* for 45 min at 50°C and stopped for 5 min at 85°C, according to manufacturer's instructions. PCR was subsequently performed using primers in *ATXN3* exon 4 and 11 (see Table 2) with 1 μ l cDNA as input. The PCR reaction contained 0.25mM dNTPs, 1U Faststart Taq DNA polymerase (Roche) and 10 pmol forward and reverse primers (Eurogentec, Liège, Belgium). PCR cycling was started with 4 min initial denaturation at 95°C, followed by a total of 36 cycles with 30 sec. of denaturation at 95°C, 30 sec of annealing at 59°C, and 1 min extension at 72°C. At the end of the program a final elongation step of 7 min at 72°C was used. PCR products were separated by electrophoresis on a 1.5% agarose gel containing 0.002% ethidium bromide. Bands of skipped products were excised from the gel, purified using a DNA extraction kit (Machery Nagel, Düren, Germany) according to manufacturer's instructions and the sequence was obtained by Sanger sequencing (Macrogen, Amsterdam, the Netherlands).

Protein isolation and western blotting

Protein from transfected cells was isolated by trypsinization and centrifugation of cells, after which the pellet was dissolved in Radioimmunoprecipitation assay (RIPA) buffer. Protein from \sim 30 mg mouse brain tissue was isolated by homogenisation with a bullet blender BBX24 for 3 min at intensity 8, in 500 µl RIPA buffer with 0.5 mm glass beads. Next, protein lysates were incubated in a head-over-head rotor at 4°C for 30 min. Protein concentration was determined using the bicinchoninic acid kit (Thermo Fisher Scientific), with bovine serum albumin as a standard. Protein samples were separated using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with Laemmli sample buffer after boiling for 5 min at 100°C. Proteins were blotted onto a nitrocellulose membrane using the Transblot Turbo system (Bio-Rad, Hercules, USA) for 10 min at 1.3 A. Blocking of membranes was done with 5% low fat milk powder in tris buffered saline (TBS) for 1 hour at room temperature. Membranes were stained using mouse anti-ataxin-3 1H9 (Abcam, Cambridge, UK) at 1:5000 dilution and rabbit anti-tubulin (Proteintech, Rosemont, IL, USA) 1:1000 overnight at 4°C. Blots were washed and incubated for 1 hour with Odyssey secondary antibodies, goat-anti-mouse IRDye 680RD or goat-anti-rabbit IRDye 800CW (LI-COR Biosciences, Lincoln, USA) at a 1:5000 dilution. Membranes were scanned using the Odyssey infrared imaging system (LI-COR). Protein bands were quantified with the Odyssey software version 3.0 using the integrated intensity method. Percentage of protein modification was calculated based on band intensities as follows: modified ataxin-3 / (modified ataxin-3 + human ataxin-3 84Q) * 100.

Cryosectioning and immunohistochemistry

Sectioning of paraformaldehyde fixed mouse brains from four control AON and three 10.4 AON treated mice was performed using a Leica CM3050 cryostat. Sagittal sections of 25 μ m thickness from the right hemisphere were immediately transferred as free floating sections to PBS containing 0.02% sodium azide at room temperature. Sections were stored at 4°C until staining. Prior to staining, sections were washed three times in PBS with 0.2% triton-X100 for 10 min and incubated with M.O.M. mouse IgG blocking reagent (Vector Laboratories, Burlingame, USA) for 1 hour. Sections were washed and incubated overnight at 4 °C with primary antibodies diluted in M.O.M. protein concentrate diluent (Vector Laboratories). Primary antibodies used were: mouse anti-ataxin-3 1H9 1:1000 (Abcam, Cambridge, UK) and rabbit anti-tyrosine hydroxylase 1:500 (Santa Cruz biotechnology, Dallas, USA). For assessment of AON distribution, a rabbit antibody binding the phosphorothioate backbone of AONs was used at 1:10.000 diluted in 1% normal goat serum. After washing, sections were incubated with secondary antibodies, goat anti-mouse-alexa Fluor 594 or goat anti-rabbit-alexa Fluor 488 (Life technologies, Paisley, UK) at 1:500 dilution. Sections were mounted on superfrost plus coated

microscope slides (Fisher Emergo, Landsmeer, Netherlands), coverslipped using EverBrite hardset mounting medium containing DAPI (Biotium, Hayward, USA) and cured overnight prior to fluorescent microscopic examination using a Leica DM-5500 using 63x magnification for assessment of ubiquitin binding or Keyence Biorevo BZ-9000 fluorescent microscope for all other analyses at 10x magnification.

Image analysis of ataxin-3 nuclear intensity

Fluorescent images of substantia nigra were analysed using ImageJ (version 1.48).²⁷ Images were converted to 8 bit and the substantia nigra was automatically selected using a region of interest based on positive tyrosine hydroxylase green fluorescence (threshold 25-254). Within this region, ataxin-3 nuclear staining was determined using the analyse particles function (circularity 0.15-1.00) based on red fluorescent staining (threshold 35-254). Background fluorescence (intensity 35) was subtracted and the average fluorescence intensity per cell was subsequently used to represent intensity of nuclear ataxin-3. Identical analysis values were used to analyse all images. Between 400 and 1300 individual cells were assessed for 10.4 and control AON treated mice.

Dot-blot filter retardation assay

To detect aggregated ataxin-3 protein, mouse brain lysates in RIPA buffer were diluted in PBS to a final concentration of 0.15 μ g/ μ l with 0.025% SDS. A total volume of 200 μ l lysate was then passed through a cellulose acetate membrane of 0.2 μ m (Whatman, Maidstone, UK) mounted in a 96-well vacuum manifold. Three additional washes were performed using PBS to remove unbound protein. The membrane was blocked using 5% non-fat milk and subsequently stained for 3 hours with mouse anti-ataxin-3 1H9 1:5000 (Abcam), and 1 hour with goat-anti-mouse IRDye 800CW 1:10.000 (LI-COR). Dots were quantified with the Odyssey software version 3.0 using the integrated intensity method.

Plasmids and mutations

Plasmids for transfection were obtained as previously described.²⁵ In short, PCR products for cloning were generated with primers flanking the full length *ATXN3* transcript (see Table 2) using AON transfected fibroblast cDNA as template. Full length or exon 10 skipped products were gel extracted, purified and ligated in the pGEM-T Easy vector (Promega) using the 5′-A overhangs. Mutations of the UIMs and deletion of cysteine 14 was generated using the QuickChange II Site Directed Mutagenesis kit (Agilent Technologies, Waldbronn, Germany) as described previously using primers containing the mutation (Table 2).²⁴ Expanded ataxin-3 with 71Q was obtained by genesynthesis (Genscript, Piscataway, USA), a mixture of CAG and CAA codons was generated to improve stability during the cloning process. Constructs were then subcloned into the PacGFP-C1 vector (Clontech, Mountain View, USA) using notI digestion, resulting in an N-terminally GFP tagged ataxin-3 protein expression. The mCherry-LacR-RNF8 construct has been described previously.²⁸ Purified ataxin-3 proteins were produced using the Pet28a vector (Merck Millipore, Billerica, USA) and BL21 *E.coli* (New England BioLabs, Ipswich, USA) as previously described.²⁵ All constructs were verified using Sanger sequencing.

Assessment of ubiquitin binding through RNF8 chromatin tethering

Ubiquitin binding assays were performed as previously described.²⁵ Briefly, human U2OS 2-6-3 cells with LacO repeats integrated in the genome²³ were grown on glass cover slips. Cells were transfected with both mCherry-LacR-RNF8²⁸ and GFP-ataxin-3 constructs. The cells were fixed in 4% paraformaldehyde the following day and glass slides were mounted on microscope slides with Everbrite mounting medium containing DAPI (Biotium, Corporate Place Hayward, US). Images were obtained for a minimum of 50 cells (2 replicate transfections) positive for both RNF8 and ataxin-3 fluorescent signals. Due to the LacR fusion, the RNF8 protein construct localises to the lacO repeat, resulting in local chromatin ubiquitination. Subsequently, ataxin-3 proteins localise to the ubiquitinated chromatin through their UIMs, resulting in colocalisation with the mCherry-RNF8. The GFP intensity, thus representing ubiquitin binding was quantified. By drawing a line region of interest across the mCherry-LacR-RNF8-marked array, the increase in GFP-ataxin-3 at the array was determined using the LAS AF Lite software (Leica Microsystems). The signal was background corrected by subtracting background GFP signal from the peak GFP intensity at the array.

Deubiquitination assay

The in vitro deubiquitination assay was performed as previously described.²⁹

1.2 μg HIS-ataxin-3 proteins were incubated with 0.5 μg K63 linked hexa-ubiquitin chains (Boston Biochem, Cambridge, USA) in buffer containing 50 mM HEPES pH 8, 0.5 mM EDTA and 1 mM DTT. Incubations were performed for 16h at 37 $^{\circ}$ C. Reactions were stopped with 4x Laemmli sample buffer containing β-mercaptoethanol and by boiling the sample at 100 $^{\circ}$ C for 5 minutes. Samples were run on SDS-PAGE using 10% TGX gels (Biorad, Hercules, USA). After Western blotting, membranes were probed with anti-ataxin-3 1H9 (1:5000) and anti-ubiquitin 1:1000 (UG9511) (Enzo life sciences, Farmingdale, USA).

Statistical analyses

The percentage of ataxin-3 protein modification, filtertrap assay dot intensity, and ataxin-3 ubiquitin binding assays were analysed with one-way ANOVA using Tukey's posthoc multiple comparisons test. Raw intensity values obtained from Oyssey application software 'integrated intensity quantification' method were used for analyses of filtertrap assays and western blots. Western blot protein modification is reported as percentage modified ataxin-3 of the sum of all human ataxin-3 bands. Intensity of nuclear ataxin-3 accumulation in substantia nigra was compared using unpaired student t-test. Statistical analyses were performed using GraphPad Prism software version 6.02. P values < 0.05 were considered statistically significant.

RESULTS

Exon 10 skip leads to a truncated ataxin-3 protein lacking the polyQ repeat

Removal of exon 10 from the ataxin-3 pre-mRNA results in a stop codon right at the start of exon 11. As a consequence, the resulting ataxin-3 protein is truncated to amino acid 291 (Fig. 1A) and lacks the C-terminal region that contains the toxic polyQ repeat, as well as UIM 3. A total of five splice modulating AONs were designed targeting exon 10 (table 1) and were transfected in SCA3 patient-derived fibroblasts. RT-PCR and western blot analysis showed that three of the tested AONs induced exon 10 skipping as both expression of a shorter ataxin-3 transcript (Δ exon 10) and truncated protein (Δ C-terminus) were observed (Fig. 1B and C). Although AON 10.4 contained a SNP (rs12895357) associated with the expanded allele,^{30, 31} we always observed modification of both wild type and mutant alleles.




Figure 1. Antisense oligonucleotide mediated removal of the polyglutamine repeat from the ataxin-3 protein. (A) Schematic representation of the experimental approach to remove exon 10 from the ataxin-3 mRNA approach based on transcript ENST00000558190 (361 amino acids) using antisense oligonucleotides (AONs) targeting predicted splicing motifs within exon 10. Skipping of exon 10 leads to a novel stop codon at the start of exon 11. The resulting ataxin-3 protein contains 291 amino acids and lacks the polyQ repeat and C-terminus (depicted as transparent region). Five different AONs against exon 10 were tested for functionality by transfection in SCA3 patient derived fibroblasts. An internally truncated ataxin-3 RNA lacking the CAG repeat (Δ exon 10) (in (B)) and a truncated ataxin-3 protein lacking the polyQ-containing C-terminus (Δ C-terminus) (in (C)) were detected. Nt = nucleotides.

Ataxin-3 lacking polyQ binds and cleaves ubiquitin chains similar to wildtype

Due to the novel stop codon in exon 11 induced by exon 10 skipping, the ataxin-3 Δ C-terminus protein lacks the third UIM (Fig. 1A). To determine whether ataxin-3 Δ C-terminus was still capable of binding ubiquitin chains, we made use of a U2OS 2-6-3 cell line containing a large array of LacO repeats,²³ in which expression of mCherry-LacR-RNF8 fusion protein leads to localised ubiquitilation of the chromatin.²⁸ Ataxin-3 subsequently binds the ubiquitins as mediated by the UIMs, resulting in colocalisation between mCherry-RNF8 and GFP-ataxin-3. We have previously shown this colocalisation of ataxin-3 to the LacO array as a reliable marker for ubiquitin binding activity of ataxin-3.²⁵ Here, we tested several GFP-tagged ataxin-3 proteins for ubiquitin binding capacity (Fig. 2A). In line with previous observations, the ataxin-3 with either 10Q or 71Q can readily bind ubiquitin chains and hence colocalised with the ubiquitin moieties at the array (Fig. 2B-C). Ataxin-3 with all 3 UIMs inactivated by point mutations (L229A, L249A and L340A), termed UIMs L>A, colocalised with the ubiquitin conjugates to a significantly lower extent, confirming the specificity of the assay. Ataxin-3 Δ C-terminus colocalised with the ubiquitin conjugates at the array to a similar extent as wildtype ataxin-3, indicating that the ubiquitin chain binding capacity of the protein was retained despite lacking the third UIM.

To confirm the ubiquitin cleavage capacity of ataxin-3 Δ C-terminus, purified HIS-ataxin-3 proteins (Fig. 2D) were incubated with K63 linked hexa-ubiquitin chains. Similar to ataxin-3 10Q and 71Q, ataxin-3 Δ C-terminus was able to cleave ubiquitin chains as evidenced by the appearance of shorter ubiquitin fragments (penta- and tetra-ubiquitin) (Fig. 2E). In line with previous reports, deletion of a cysteine in the Josephin domain (Δ C14) abolished ataxin-3 ubiquitin protease activity.³² Together, these results indicate that removal of the C-terminus from ataxin-3 does not interfere with ubiquitin binding and cleavage capacity.

Ataxin-3 exon skipping in mouse brain

To determine whether the ataxin-3 exon skip strategy is feasible *in vivo*, the four AONs against *ATXN3* RNA were tested in the MJD84.2 mouse model.²⁶ The MJD84.2 mouse contains the full human *ATXN3* gene with 84 CAGs including introns and flanking regions, making it a suitable SCA3 rodent model to assess human *ATXN3* splicing events *in vivo*. Sequencing analysis showed that the human *ATXN3* gene in this mouse also contains the SNP (rs12895357), and thus has full complementarity with AON 10.4 (data not shown). To assess AON efficacy, the AONs targeting exon 10 were injected as a single 500 µg ICV bolus in anesthetized hemizygous MJD84.2 mice. Two weeks after the injection, exon skipping was analysed in cortex and cerebellum (Fig. 3A). AON efficacy in both brain regions was similar to that observed in SCA3 fibroblasts transfections, with AON 10.4 being most efficient. Sanger sequencing confirmed that the shorter *ATXN3* RNA was the result of exon 10 skipping in the human transcript. In line with the transcript modification, a modified Δ C-terminus ataxin-3 protein of approximately 36 kDa in size was observed in the treated animals (Fig. 3B). Protein modification appeared more efficient in cortex than cerebellum. In the untreated animals, an ataxin-3 protein of similar size as Δ C-terminus




Figure 2. Ataxin-3 Δ C-terminus is capable of binding and cleaving ubiquitin chains. (A) Schematic representation of mCherry and GFP fusion proteins with their functional domains. The ubiquitin ligase RNF8 was fused to mCherry and LacR. Atatxin-3 was fused to GFP. Ubiquitin-interacting motifs (UIMs) of ataxin-3 are depicted in blue. Inactivating substitution mutations are indicated by red crosses (B) Tethering of the mCherry-LacR-RNF8 fusion protein to a LacO array in the chromatin in U2OS 2-6-3 cells (red signal) results in local chromatin ubiquitylation at the LacO array.²⁸ GFP-ataxin-3 proteins bind the RNF8-induced ubiquitin moieties at the the lacO array, thereby colocalizing with mCherry-LacR-RNF8 (green).²⁵ Representative images are shown. Arrows indicate the chromatin localised RNF8 and ataxin-3 where GFP intensity was quantified. (C) Quantification of increase in GFP-tagged ataxin-3 signal at the array after co-expression with mCherry-LacR-RNF8. Values represent the mean +SEM of >40 cells examined from two independent experiments. (D) Schematic representation of HIS-tagged ataxin-3 proteins used in ubiquitin cleavage reaction. The C14 deletion (Δ C14) is known to inactivate catalytic activity. (E) Purified HIS-ataxin-3 proteins were incubated for 16h with K63-linked hexa-ubiquitin to determine ubiquitin cleavage activity.




Figure 3. AON screening *in vivo*. 500µg AON was injected intracerebroventricularly in MJD84.2 mice. After 2 weeks, mice were sacrificed and RNA and protein was isolated from cortex and cerebellum. (A) RT-PCR using primers flanking *ATXN3* exon 10 shows the full length human ataxin-3 PCR product with 84 CAG repeats, the mouse ataxin-3 with 6 CAG repeats as well as the shorter ataxin-3 lacking exon 10 after injection of AON 10.1 and 10.4 (Δ exon 10). Sanger sequencing trace of Δ exon 10 RNA is shown below with corresponding reading frame. (B) Western blotting shows the full length human ataxin-3 protein with 84 Q repeats, the mouse ataxin-3 protein with 6 Qs and the truncated ataxin-3 protein lacking the C-terminus. Of the 4 AONs tested, AON 10.1 and 10.4 show the most efficient modification of the human ataxin-3 protein (Δ C-terminus). Ctx = cortex, cb = cerebellum.

ataxin-3 was observed as well, perhaps indicating the truncated ataxin-3 protein is a naturally occurring isoform or cleavage fragment in these mice.

AON effect lasts at least 2.5 months in mouse brain

Despite relatively high expression of mutant ataxin-3 throughout the brain, hemizygous MJD84.2 mice do not develop an ataxic phenotype on beamwalk tests,³³ but do develop a neuronal phenotype consisting of nuclear localisation of mutant human ataxin-3 in certain neuronal populations from around 2 months of age.^{33, 34} To assess long term efficacy of AONs in the mouse brain and the effect on the neuronal phenotype, a total of 27 mice were treated with either PBS, scrambled control AON or AON 10.4 and sacrificed 2.5 months after the last injection. With repeated injections, a total ICV dose of 1 mg AON was achieved over a 3 week period (Fig. 4A). There was a clear dose dependent effect on protein modification, with a 500 µg dose resulting in 17% protein modification in cortex, and 1 mg AON resulting in 37% protein modification (supplementary Fig. 1). At the time of sacrifice, ATXN3 exon 10 skipping was seen at RNA level in all tested brain regions (Fig. 4B and supplementary Fig. 2A), 40% ataxin-3 modification was seen in protein lysates from brainstem and cortex, while 20% ataxin-3 modification was seen in cerebellum (Fig. 4C-D and supplementary Fig. 2B). This indicates that the AONs have distributed throughout the brain, and are stable and effective for at least 2.5 months post injection. No deleterious effect of the AON on bodyweight or motor behaviour (supplementary Fig. 3) was observed during the course of the study.

AON treatment reduces insoluble ataxin-3 and prevents nuclear accumulation

Protein aggregation is considered a hallmark of polyQ disorders. It has been implicated as a pathogenic mechanism for these diseases^{35, 36} and mutant ataxin-3 aggregates are found

5




Figure 4. in vivo assessment of AON mediated removal of the ataxin-3 polyglutamine repeat in MJD84.2 mice. (A) Schematic representation of experimental design. At ~2.5 months of age (timepoint 0), mice were cannulated and 500 µg of AON 10.4 was injected ICV. Additional 250 µg injections were performed at week 3 and 4 resulting in a total dose of 1 mg. Mice were sacrificed after 3.5 months. n = 6 per group (B) RT-PCR specific for human ATXN3 with primers flanking exon 10 shows full-length mutant ataxin-3 and ataxin-3 lacking exon 10 (Δ exon 10) in treated mice. (C) Modified ataxin-3 protein was seen for AON treated transgenic mice in all tested brain regions: brainstem and cortex are shown. Each lane represents one mouse. (D) Quantification of band intensity from C shows up to 40% ataxin-3 modification. Reported is modified ataxin-3 percentage of the sum of mutant and modified ataxin-3 band intensities. (E) Staining with an antibody against the phosphorothioate backbone shows that AONs are located throughout the entire mouse brain following ICV infusion. Upper panel shows a mouse sacrificed three months after injection with AON 10.4, lower panel depicts PBS injected mouse. Higher magnification of the cerebellum shows good AON uptake in the Purkinje cells. (F) Filter retardation assay indicates that mice carrying the transgene show insoluble ataxin-3 in all tested brain regions when stained with 1H9 anti-ataxin-3 antibody. A reduction in insoluble ataxin-3 is seen in AON 10.4 treated animals compared to PBS and control AON treated animals. (G) Quantification of dot intensity from F reveals significant reduction in filter trapped insoluble ataxin-3 protein in AON 10.4 treated mice. * p < 0.05 ** p < 0.01




Figure 5. AON treatment reduces nuclear ataxin-3 accumulation in substantia nigra of SCA3 mice. (A) The nuclear accumulation of ataxin-3 was determined by staining with the 1H9 monoclonal antibody. Only cells of the substantia nigra expressing tyrosine hydroxylase were used in this analysis, as these showed the most intense nuclear ataxin-3 signal. (B) Quantification of staining intensity revealed that transgenic mice treated with 10.4 AON showed a decrease in nuclear ataxin-3 accumulation, likely due to the reduction in full length mutant ataxin-3 levels. Analysis performed on four control AON vs three 10.4 AON treated mice and four sections per mouse. Mean + SEM, evaluated with student t-test, ** p < 0.01

in the brain of SCA3 patients.³⁷ Using protein lysates from three different brain regions, we performed filter trap assays³⁸ to detect the level of insoluble ataxin-3 proteins (Fig. 4F). Insoluble ataxin-3 protein was detected in the transgenic MJD84.2 mice expressing mutant ataxin-3, but not in wildtype mice. The highest level of insoluble ataxin-3 was detected in the cerebellum. No significant difference in ataxin-3 insolubility was observed between scrambled AON and PBS treated SCA3 animals. Following AON 10.4 treatment, there was significantly less insoluble ataxin-3 detected compared to animals treated with scrambled AON or PBS (Fig. 4G).

To further assess the effect of AON treatment on expanded ataxin-3 pathogenicity, we performed immunofluorescent examination of SCA3 mouse brains in mice that were ~5.5 months of age at time of sacrifice. We observed strong nuclear ataxin-3 staining throughout the brainstem but specifically in the substantia nigra. Nuclear accumulation of expanded ataxin-3 has been shown to aggravate neurodegeneration and formation of aggregates *in vivo*,³⁹ and is therefore a useful marker to assess ataxin-3 toxicity. In fact, nuclear localisation of ataxin-3 appears to be required to induce symptoms of SCA3.³⁹ In the MJD84.2 mouse model, we observed strong nuclear localisation of ataxin-3 in the substantia nigra. Therefore, we used tyrosine hydroxylase staining to delineate the substantia nigra in sagittal brain sections (Fig. 5A). The intensity of ataxin-3 nuclear localisation in the substantia nigra was markedly reduced in mice treated with 10.4 AON when compared to animals treated with control AON (Fig. 5B).

DISCUSSION

In this work we describe an AON mediated exon skipping strategy for SCA3. Our therapeutic approach removes the polyQ repeat from the protein and therefore removes the cause of SCA3. This approach is superior to current treatments that only treat symptoms and not the cause of disease. It may also have some specific advantages over strategies that aim to lower expression of the ataxin-3 protein, since ataxin-3 has important cellular functions⁴⁰ in regulating protein degradation,³² transcription⁴¹ and DNA damage response.²⁹ Though ataxin-3 knockout appears tolerated in mice without major deficits,⁴²⁻⁴⁴ it is currently unknown whether long-term downregulation will be tolerated in patients. Therefore, it is more prudent to avoid complete ataxin-3 downregulation. We provide evidence that repeated ICV injections of AONs in a transgenic SCA3 mouse model leads to substantial ataxin-3 RNA and protein modification (ataxin-3 Δ C-terminus) throughout the mouse brain, and is able to alleviate ataxin-3 nuclear accumulation and insolubility.

Ataxin-3 Δ C-terminus still contains the main known functional domains, namely the catalytic Josephin domain (aa 1-180) and the VCP interacting motif (aa 257–291).⁴⁵ The Josephin domain is required for ataxin-3 deubiquitinating activity,⁴⁶ in conjunction with UIM1 and 2 coordinating specific ubiquitin chain cleavage.^{11, 12} The UIMs are required for the ubiquin binding capacity of ataxin-3, but the third UIM is not considered essential for this process.^{10, 11, 24, 47} The current study confirms this by showing wildtype ubiquitin binding capacity of Δ C-terminus ataxin-3 in a cellular context (Fig. 2B-C). Previous experiments have shown that removing the C-terminus form ataxin-3 does not impair its de-ubiquitinating activity.⁴⁸ Our results are in line with these previous studies and show that ataxin-3 Δ C-terminus is capable of cleaving ubiquitin chains (Fig. 2E).

Ataxin-3 interaction with VCP is thought to be crucial for the activation of ataxin-3 and regulating the endoplasmic reticulum-associated degradation pathway through protein extraction from the endoplasmic reticulum.^{49, 50} Ataxin-3 Δ C-terminus still contains the VCP binding motif. ⁴⁵ Retainment of the VCP binding site in ataxin-3 Δ C-terminus may be of particular importance, as a mouse model expressing only the ataxin-3 N-terminus up to amino acid 259 resulted in extranuclear neuronal aggregates and premature death at 12 months of age.⁵¹ This phenotype was associated with disturbances of endoplasmic reticulum-mediated unfolded protein response, possibly indicating the importance of ataxin-3 and VCP interaction in maintaining endoplasmic reticulum homeostasis.

A recent study by Liu and colleagues testing several different oligonucleotide chemistries found that ATXN3 exon 10 could be skipped with CAG targeting oligonucleotides and the ataxin-3 Δ C-terminus protein was also observed in these experiments.⁵² Both mutant and wildtype ataxin-3 alleles will be targeted by the AON, as the AON is complementary to the canonical exon 10 sequence. Indeed, we observed a similar level of exon skipping for the mutant and wildtype allele in SCA3 patient derived fibroblasts (Fig.1B and C). This observation underlines the importance of determining protein function of ataxin-3 Δ C-terminus in a neuronal context, as the proposed AON treatment may lead to high protein modification levels throughout the brain.

Apart from retaining wild-type ataxin-3 function, an important concern is that the ataxin-3 Δ C-terminus protein should not result in a gain of toxic function. An ataxin-3 protein variant corresponding exactly to the Δ C-terminus protein resulting from exon 10 skipping has been tested in a yeast model and rat cerebellar granule cells, where it was shown that this protein indeed did not aggregate, but in some tests showed a mild increase in toxicity compared to the wildtype ataxin-3 protein.^{53, 54} Whether these results can be extrapolated to the *in vivo* situation will have to be determined, but we did not observe overt signs of toxicity in the AON 10.4 treated mice expressing ataxin-3 Δ C-terminus based on bodyweight and locomotor activity (supplementary Fig. 3A and B). Additionally, no increase in cell death was observed in fibroblasts treated with AON 10.4 (Fig. 1C), or U2OS cells transfected with GFP- ataxin-3 Δ C-terminus (Fig. 2B), indicating that ataxin-3 Δ C-terminus is not toxic to these cells. Interestingly, a study investigating the transcript diversity of ataxin-3 in humans found two naturally occurring ataxin-3 isoforms generated by a stop codon after exon 9. Indeed, we observed an ataxin-3 protein of similar size to our Δ C-terminus protein in untreated SCA3 animals (Fig. 3B), perhaps indicating that this protein is also expressed in the transgenic mouse brain. If ataxin-3 Δ C-terminus is indeed a naturally occurring isoform, this may suggest that the protein is likely not a toxic variant. To more comprehensively test whether ataxin-3 Δ C-terminus is fully functional and not toxic to cells, it will be useful to express ataxin-3 Δ C-terminus in ataxin-3 knockout mice in future studies.

The current study used the MJD84.2 mouse model.²⁶ This mouse model contains the full human *ATXN3* gene, including flanking regions and introns which is essential when testing splice modulating AONs. Indeed, similar potency of the exon 10 targeting AONs were found when comparing patient derived fibroblast results with the *in vivo* ICV injections. Repeated bolus injections of AON 10.4 were tolerated and led to increased levels of ataxin-3 protein modification. No significant reduction in the level of soluble mutant ataxin-3 with western blot analysis (Fig. 4C), however a reduction in the amount of insoluble ataxin-3 was observed in the filtertrap assay (Fig. 4F).

We did not consistently observe strong nuclear accumulation of ataxin-3 in the deep cerebellar nuclei as previously reported in the MJD84.2 mice.³⁴ Though we were not able to detect clear aggregates in any brain regions, ataxin-3 nuclear localisation was readily seen in the substantia nigra, in line with previous reports.⁵⁵ The molecular SCA3 phenotype of the mice was beneficially effected by AON treatment, with a reduction of insoluble ataxin-3 species observed in filtertrap assays, and less nuclear ataxin-3 accumulation in the substantia nigra. The AONs were functionally active for at least 2.5 months, in line with previous studies using similar AON chemistries in spinal muscular atrophy mice reporting effects lasting for over 6 months after ICV injection.⁵⁶

Clinical application of AONs currently seem promising. In clinical trials, intrathecal injection of MOE modified AONs in children with spinal muscular atrophy have shown AON half-lives in the CSF of 4-6 months, with good tolerability and improvement in patients motor

function.⁵⁷ This suggests that relatively infrequent dosing, such as intrathecal AON injections every 6 months, could be a feasible treatment regimen for SCA3. The removal of the polyQ repeat from ataxin-3 is likely to delay disease progression and restrict brain damage. In case of high efficacy of the treatment it could even stop disease progression completely. Since the mouse model used here does not present with ataxic symptoms, we were unable to assess an effect of our AON treatment on reversal of the motor phenotype. However, studies in mice where expression of mutant ataxin-3 was halted during early stage disease have shown that a reversal of the motor symptoms was possible.⁵⁸ A similar observation has been made when polyQ expanded Huntingtin protein was downregulated using AONs in a Huntington's disease mouse model.⁵⁹ This is a promising observation, but whether the same could be possible in humans is currently unknown. Because of the autosomal dominant nature of SCA3, patients can start therapy before onset of clinical symptoms, improving likelihood of a beneficial effect.

AUTHOR CONTRIBUTIONS

Research conception and experiment design by: W.M.C.vR-M, L.J.A.T., F.R. and H.v.A. Experiments performed and manuscript written by L.J.A.T. Revision to manuscript by W.M.C.vR-M, H.v.A and F.R.

ACKNOWLEDGEMENTS

The authors want to thank Maarten Schenke, Barry Pepers, Martijn Luijsterburg and Melvin Evers for advice on experimental setup and Maurice Overzier and Wouter Wiegant for practical assistance. The authors are grateful to Susan Janicki and Roger Greenberg for providing U2OS 2-6-3 cells. This work was financially supported by ZonMw 40-41900-98-018 and Hersenstichting/ Brugling Fund (BG2013-03) to W.M.C.vR-M.

REFERENCES


- 1. Rub, U, Schols, L, Paulson, H, Auburger, G, Kermer, P, Jen, JC, *et al.* (2013). Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. *Prog Neurobiol* **104**: 38-66.
- 2. Riess, O, Rub, U, Pastore, A, Bauer, P, and Schols, L (2008). SCA3: neurological features, pathogenesis and animal models. *Cerebellum (London, England)* 7: 125-137.
- 3. Orr, HT, and Zoghbi, HY (2007). Trinucleotide repeat disorders. Annual review of neuroscience 30: 575-621.
- 4. Kawaguchi, Y, Okamoto, T, Taniwaki, M, Aizawa, M, Inoue, M, Katayama, S, *et al.* (1994). CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. *Nature genetics* **8**: 221-228.
- 5. Cummings, CJ, and Zoghbi, HY (2000). Trinucleotide repeats: mechanisms and pathophysiology. *Annual review of genomics and human genetics* 1: 281-328.
- 6. Matos, CA, de Macedo-Ribeiro, S, and Carvalho, AL (2011). Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. *Prog Neurobiol* **95**: 26-48.
- Bettencourt, C, Raposo, M, Ros, R, Montiel, R, Bruges-Armas, J, and Lima, M (2013). Transcript diversity of Machado-Joseph disease gene (ATXN3) is not directly determined by SNPs in exonic or flanking intronic regions. *Journal of molecular neuroscience : MN* 49: 539-543.
- 8. Harris, GM, Dodelzon, K, Gong, L, Gonzalez-Alegre, P, and Paulson, HL (2010). Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. *PloS one* 5: e13695.
- 9. Schmidt, T, Landwehrmeyer, GB, Schmitt, I, Trottier, Y, Auburger, G, Laccone, F, *et al.* (1998). An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. *Brain pathology (Zurich, Switzerland)* **8**: 669-679.
- 10. Chai, Y, Berke, SS, Cohen, RE, and Paulson, HL (2004). Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. *J Biol Chem* **279**: 3605-3611.
- 11. Mao, Y, Senic-Matuglia, F, Di Fiore, PP, Polo, S, Hodsdon, ME, and De Camilli, P (2005). Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. *Proceedings of the National Academy of Sciences of the United States of America* **102**: 12700-12705.
- 12. Winborn, BJ, Travis, SM, Todi, SV, Scaglione, KM, Xu, P, Williams, AJ, *et al.* (2008). The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. *The Journal of biological chemistry* **283**: 26436-26443.
- 13. Alves, S, Nascimento-Ferreira, I, Dufour, N, Hassig, R, Auregan, G, Nobrega, C, *et al.* (2010). Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? *Hum Mol Genet* 19: 2380-2394.
- 14. Alves, S, Nascimento-Ferreira, I, Auregan, G, Hassig, R, Dufour, N, Brouillet, E, *et al.* (2008). Allelespecific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. *PLoS One* **3**: e3341.
- 15. Conceicao, M, Mendonca, L, Nobrega, C, Gomes, C, Costa, P, Hirai, H, *et al.* (2015). Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype. *Biomaterials* 82: 124-137.
- 16. Nobrega, C, Nascimento-Ferreira, I, Onofre, I, Albuquerque, D, Hirai, H, Deglon, N, *et al.* (2013). Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. *PloS one* **8**: e52396.

5

- 17. Evers, MM, Toonen, LJ, and van Roon-Mom, WM (2015). Antisense oligonucleotides in therapy for neurodegenerative disorders. *Advanced drug delivery reviews* **87**: 90-103.
- 18. Aartsma-Rus, A (2012). Overview on AON design. Methods Mol Biol 867: 117-129.
- Aartsma-Rus, A, van Vliet, L, Hirschi, M, Janson, AA, Heemskerk, H, de Winter, CL, et al. (2009). Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Molecular therapy : the journal of the American Society of Gene Therapy 17: 548-553.
- 20. Desmet, FO, Hamroun, D, Lalande, M, Collod-Beroud, G, Claustres, M, and Beroud, C (2009). Human Splicing Finder: an online bioinformatics tool to predict splicing signals. *Nucleic Acids Res* 37: e67.
- 21. Swayze, EE, Siwkowski, AM, Wancewicz, EV, Migawa, MT, Wyrzykiewicz, TK, Hung, G, *et al.* (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. *Nucleic acids research* **35**: 687-700.
- 22. Bauer, S, Kirschning, CJ, Hacker, H, Redecke, V, Hausmann, S, Akira, S, *et al.* (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. *Proceedings of the National Academy of Sciences of the United States of America* **98**: 9237-9242.
- 23. Janicki, SM, Tsukamoto, T, Salghetti, SE, Tansey, WP, Sachidanandam, R, Prasanth, KV, *et al.* (2004). From Silencing to Gene Expression: Real-Time Analysis in Single Cells. *Cell* **116**: 683-698.
- 24. Evers, MM, Tran, HD, Zalachoras, I, Pepers, BA, Meijer, OC, den Dunnen, JT, *et al.* (2013). Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. *Neurobiology of disease* 58: 49-56.
- 25. Toonen, LJ, Schmidt, I, Luijsterburg, MS, van Attikum, H, and van Roon-Mom, WM (2016). Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3. *Sci Rep* **6**: 35200.
- 26. Cemal, CK, Carroll, CJ, Lawrence, L, Lowrie, MB, Ruddle, P, Al-Mahdawi, S, *et al.* (2002). YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. *Human molecular genetics* **11**: 1075-1094.
- 27. Schneider, CA, Rasband, WS, and Eliceiri, KW (2012). NIH Image to ImageJ: 25 years of image analysis. *Nature methods* **9**: 671-675.
- Luijsterburg, MS, Acs, K, Ackermann, L, Wiegant, WW, Bekker-Jensen, S, Larsen, DH, et al. (2012). A new non-catalytic role for ubiquitin ligase RNF8 in unfolding higher-order chromatin structure. The EMBO Journal 31: 2511-2527.
- 29. Pfeiffer, A, Luijsterburg, MS, Acs, K, Wiegant, WW, Helfricht, A, Herzog, LK, *et al.* (2017). Ataxin-3 consolidates the MDC1-dependent DNA double-strand break response by counteracting the SUMO-targeted ubiquitin ligase RNF4. *Embo j.*
- 30. Gaspar, C, Lopes-Cendes, I, Hayes, S, Goto, J, Arvidsson, K, Dias, A, *et al.* (2001). Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. *American journal of human genetics* **68**: 523-528.
- 31. Michlewski, G, and Krzyzosiak, WJ (2004). Molecular architecture of CAG repeats in human disease related transcripts. *J Mol Biol* **340**: 665-679.
- 32. Burnett, B, Li, F, and Pittman, RN (2003). The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. *Human molecular genetics* **12**: 3195-3205.


- 33. Costa Mdo, C, Luna-Cancalon, K, Fischer, S, Ashraf, NS, Ouyang, M, Dharia, RM, *et al.* (2013). Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. *Molecular therapy : the journal of the American Society of Gene Therapy* **21**: 1898-1908.
- Rodriguez-Lebron, E, Costa Mdo, C, Luna-Cancalon, K, Peron, TM, Fischer, S, Boudreau, RL, et al. (2013). Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Molecular therapy : the journal of the American Society of Gene Therapy 21: 1909-1918.
- 35. Chen, S, Ferrone, FA, and Wetzel, R (2002). Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. *Proceedings of the National Academy of Sciences of the United States of America* **99**: 11884-11889.
- 36. Holmes, WM, Klaips, CL, and Serio, TR (2014). Defining the limits: Protein aggregation and toxicity in vivo. *Critical reviews in biochemistry and molecular biology* **49**: 294-303.
- 37. Koch, P, Breuer, P, Peitz, M, Jungverdorben, J, Kesavan, J, Poppe, D, *et al.* (2011). Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. *Nature* **480**: 543-546.
- 38. Wanker, EE, Scherzinger, E, Heiser, V, Sittler, A, Eickhoff, H, and Lehrach, H (1999). Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. *Methods in enzymology* **309**: 375-386.
- 39. Bichelmeier, U, Schmidt, T, Hubener, J, Boy, J, Ruttiger, L, Habig, K, *et al.* (2007). Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **27**: 7418-7428.
- 40. Evers, MM, Toonen, LJ, and van Roon-Mom, WM (2014). Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies. *Mol Neurobiol* **49**: 1513-1531.
- Evert, BO, Araujo, J, Vieira-Saecker, AM, de Vos, RA, Harendza, S, Klockgether, T, et al. (2006). Ataxin-3
 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone
 deacetylation. The Journal of neuroscience : the official journal of the Society for Neuroscience 26: 11474-11486.
- 42. Moore, LR, Rajpal, G, Dillingham, IT, Qutob, M, Blumenstein, KG, Gattis, D, *et al.* (2017). Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models. *Molecular therapy Nucleic acids* 7: 200-210.
- 43. Schmitt, I, Linden, M, Khazneh, H, Evert, BO, Breuer, P, Klockgether, T, *et al.* (2007). Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. *Biochemical and biophysical research communications* **362**: 734-739.
- 44. Switonski, PM, Fiszer, A, Kazmierska, K, Kurpisz, M, Krzyzosiak, WJ, and Figiel, M (2011). Mouse ataxin-3 functional knock-out model. *Neuromolecular Med* **13**: 54-65.
- Boeddrich, A, Gaumer, S, Haacke, A, Tzvetkov, N, Albrecht, M, Evert, BO, *et al.* (2006). An arginine/ lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. *The EMBO journal* 25: 1547-1558.
- 46. Nicastro, G, Todi, SV, Karaca, E, Bonvin, AM, Paulson, HL, and Pastore, A (2010). Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3. *PloS one* 5: e12430.
- 47. Donaldson, KM, Li, W, Ching, KA, Batalov, S, Tsai, CC, and Joazeiro, CA (2003). Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. *Proceedings of the National Academy of Sciences of the United States of America* **100**: 8892-8897.

- 48. Tzvetkov, N, and Breuer, P (2007). Josephin domain-containing proteins from a variety of species are active de-ubiquitination enzymes. *Biological chemistry* **388**: 973-978.
- 49. Laco, MN, Cortes, L, Travis, SM, Paulson, HL, and Rego, AC (2012). Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3. *PloS one* 7: e43563.
- 50. Zhong, X, and Pittman, RN (2006). Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates. *Hum Mol Genet* 15: 2409-2420.
- 51. Hubener, J, Vauti, F, Funke, C, Wolburg, H, Ye, Y, Schmidt, T, *et al.* (2011). N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. *Brain : a journal of neurology* **134**: 1925-1942.
- 52. Liu, J, Yu, D, Aiba, Y, Pendergraff, H, Swayze, EE, Lima, WF, *et al.* (2013). ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy. *Nucleic acids research* **41**: 9570-9583.
- 53. Bonanomi, M, Visentin, C, Invernizzi, G, Tortora, P, and Regonesi, ME (2015). The Toxic Effects of Pathogenic Ataxin-3 Variants in a Yeast Cellular Model. *PloS one* **10**: e0129727.
- 54. Pellistri, F, Bucciantini, M, Invernizzi, G, Gatta, E, Penco, A, Frana, AM, *et al.* (2013). Different ataxin-3 amyloid aggregates induce intracellular Ca(2+) deregulation by different mechanisms in cerebellar granule cells. *Biochimica et biophysica acta* **1833**: 3155-3165.
- 55. Chen, X, Tang, TS, Tu, H, Nelson, O, Pook, M, Hammer, R, *et al.* (2008). Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **28**: 12713-12724.
- 56. Rigo, F, Chun, SJ, Norris, DA, Hung, G, Lee, S, Matson, J, et al. (2014). Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. *The Journal of pharmacology and experimental therapeutics* **350**: 46-55.
- 57. Chiriboga, CA, Swoboda, KJ, Darras, BT, Iannaccone, ST, Montes, J, De Vivo, DC, *et al.* (2016). Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. *Neurology* **86**: 890-897.
- 58. Boy, J, Schmidt, T, Wolburg, H, Mack, A, Nuber, S, Bottcher, M, *et al.* (2009). Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. *Hum Mol Genet* **18**: 4282-4295.
- Kordasiewicz, HB, Stanek, LM, Wancewicz, EV, Mazur, C, McAlonis, MM, Pytel, KA, et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. *Neuron* 74: 1031-1044.




SUPPLEMENTARY FIGURES

Supplementary Figure 1. Comparison of 500 μ g and 1 mg AON 10.4 ICV bolus. AON 10.4 was tested *in vivo* by ICV injection in two mice to determine dose response. 500 μ g AON was injected at 2.5 months of age, after which one of the mice was injected with a second 500 μ g bolus 2 weeks later. Both mice were sacrificed 2 weeks after the last injection. Westernblot analysis and staining with 1H9 antibody shows ataxin-3 Δ C-terminus appearing in the three brainregions tested of the treated MJD84.2 mice. A clear increase in protein modification is seen with the 1 mg dose compared to the 500 μ g dose. Cb = cerebellum, br = brainstem, ctx = cortex.



Supplementary Figure 2. In vivo assessment of exon skipping at RNA and protein level. Mice were treated with a total of 1 mg AON 10.4 or control AON, and sacrificed ~3.5 monhs after last injection. Results are obtained from mice depicted in figure 3. (A) RT-PCR with primers for human *ATXN3* show skipping of exon 10 in brainstem of AON 10.4 treated mice. (B) Modified ataxin-3 protein (Δ C-terminus) was observed in cerebellum of mice treated with AON 10.4.



Supplementary Figure 3. MJD84.2 mouse does not present obvious ataxic phenotype at 5 months of age. (A) No significant difference in bodyweight between wildtype and transgenic mice was seen, or between scrambled and AON10.4 treated mice of both genotypes. (B) Wildtype and hemizygous MJD84.2 mice were tested for motor performance in a home cage activity system at around 5 months of age. Scrambled AON: 5 wildtype vs 5 SCA3 mice. 10.4 AON: 4 wildtype vs 6 SCA3 mice.